Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 06, 2025 08:05 ET | Source: Imunon, Inc.

IMUNON Announces Data from Phase 1/2 Trial Evaluating Intraperitoneal IMNN-001 in Combination with Neoadjuvant Chemotherapy in Newly Diagnosed Patients with Advanced Epithelial Ovarian Cancer to be Published in Gynecologic Oncology

Data from OVATION 2 trial will also be reviewed in an oral presentation at ASCO Annual Meeting on June 3, 2025 LAWRENCEVILLE, N.J., May 06, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a...
April 17, 2024 03:00 ET | Source: Theolytics

Theolytics successfully closes latest financing raising total of £19M ($24.5M) and welcomes Sound Bioventures as new investor

Oxford, UK April 17th, 2024. Theolytics, a biotechnology company developing next-generation oncolytic viral therapies, today announced it has successfully closed its latest financing round, raising a...
October 05, 2021 08:00 ET | Source: VBL Therapeutics

VBL Therapeutics Announces Appointment of Sam Backenroth as Chief Financial Officer and Establishes Operations in the United States

TEL AVIV, Israel and NEW YORK, Oct. 05, 2021 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) today announced the appointment of Sam Backenroth as chief financial officer (CFO) effective...
September 17, 2021 07:00 ET | Source: VBL Therapeutics

VBL Therapeutics Announces Independent Data Safety Monitoring Committee Provides Clearance to Continue the OVAL Phase 3 Registration-Enabling Study of VB-111 in Ovarian Cancer

The OVAL Phase 3 clinical trial evaluating VB-111 in platinum-resistant ovarian cancer has recruited more than 320 patients (>80 %) to date;Remains on track to complete enrollment in 1Q22 TEL...
September 10, 2021 07:00 ET | Source: VBL Therapeutics

VBL Therapeutics to Present at Upcoming Conferences

TEL AVIV, Israel, Sept. 10, 2021 (GLOBE NEWSWIRE) -- VBL Therapeutics (NASDAQ: VBLT) today announced the Company will present in the following upcoming industry conferences: H.C. Wainwright 23rd...
August 30, 2021 07:00 ET | Source: VBL Therapeutics

VBL Therapeutics Resumes U.S. Enrollment in OVAL Phase 3 Trial as FDA Authorizes Clinical Use of VB-111 Batches Produced in Modiin Facility

U.S. FDA CMC clearance of VB-111 produced in Modiin, Israel facility an important milestone toward potential commercializationOVAL Phase 3 trial evaluating VB-111 in platinum resistant ovarian cancer...